Edwards Lifesciences (EW) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential derivative action claims on behalf of shareholders of Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (EW) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

This inquiry follows the filing of a class action complaint on October 14, 2024, which alleges that certain directors and officers of Edwards Lifesciences created the false impression that they possessed reliable information regarding the Company’s projected revenue outlook and anticipated growth. According to the complaint, the Company minimized risks related to seasonality and macroeconomic fluctuations, while in reality, the growth of the Company’s transcatheter aortic valve replacement (TAVR) procedures was at risk of decelerating.

The complaint also alleges that the Company's leadership relied too heavily on or overstated hospital demand for the Company’s TAVR procedures, despite the emergence of newer, innovative structural heart therapies. It is alleged that these misrepresentations and failures in oversight may have resulted in financial harm to the Company and its shareholders.

On July 24, 2024, Edwards Lifesciences announced lower than expected Q2 results; On this news, shares declined 31%, dropping to $59.70 per share (>31% below the previous day's trading value).

The shareholder investigation seeks to determine whether the board of directors and executive officers of Edwards Lifesciences failed to implement or monitor effective disclosure controls and oversight mechanisms related to the accuracy of the Company's financial forecasting and demand projects for its TAVR business. The investigation also concerns whether certain directors and officers may have disregarded warning signs or failed to act in good faith in connection with the Company’s public statements about TAVR growth, patient activation efforts, and hospital demand.

If you have held Edwards Lifesciences (NYSE: EW) shares continuously since at least February 2024, you may be able to seek corporate reforms, the return of funds back to the Company, and a court approved incentive award for you, all at absolutely no cost.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.